The Nationwide Complete Most cancers Community® (NCCN®) 2023 Annual Congress: Hematologic Malignancies™ returns to San Francisco this week, for the primary time since 2019. The assembly options insights from world-renowned specialists on offering optimum, evidence-based therapy for varied blood cancers, plus greatest practices for shielding weak populations in a altering healthcare panorama.
The stay occasion is going down September 22-23, 2023, on the Hilton San Francisco Union Sq.. For full particulars and to register, go to NCCN.org/hem.
“We designed a complete program for your entire hematology and oncology team-;bearing in mind the most recent advances, conversations, and controversies in blood most cancers therapy at present,” stated congress Chair Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Most cancers Middle. “Attendees from everywhere in the world can study probably the most up-to-date proof and knowledgeable consensus for bettering outcomes for sufferers with a wide range of hematologic malignancies. The occasion additionally supplies alternatives for networking and questions with main specialists within the discipline.”
The hybrid occasion is again in California for the primary time in 4 years, following final 12 months’s assembly in New York Metropolis. Attendees are additionally capable of attend stay on-line by way of NCCN’s easy-to-use digital platform. Classes will stay accessible on-demand for 60 days following the occasion for all registrants.
A few of this 12 months’s featured matters embody:
- Figuring out and managing toxicities in sufferers receiving CAR T-cell remedy
- Revolutionizing hematologic most cancers therapy with bispecific T-cell engagers
- Integrating new WHO/ICC classification programs
- Tackling inequities in entry and high quality of take care of sufferers with a number of myeloma
- Managing graft-versus-host illness in transplant recipients
- Prevention and administration of blood clots
Audio system can even share info and analysis pertaining to the therapy of Grownup Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), B-Cell Malignancies, Continual Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Continual Myeloid Leukemia, Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), A number of Myeloma (MM), Myelodysplastic Syndromes (MDS), Myelofibrosis (MF), and Waldenström Macroglobulinemia (WM).
This convention seeks to offer clear, comprehensible, and actionable updates to assist busy care suppliers analyze, consider, and contextualize new scientific information. This may assist us all to attain the absolute best outcomes for individuals with blood most cancers in a quickly evolving panorama.”
Wui-Jin Koh, MD, Senior Vice President, Chief Medical Officer, NCCN
Save the dates: the NCCN 2024 Annual Convention might be taking place in Orlando, FL April 5 – 7, 2024.